Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — 39th Annual JP Morgan Healthcare Conference 2021
16 slides from Paradigm Biopharmaceuticals's conference presentation, Jan 12, 2021
Slide 1: 39th Annual JP Morgan Healthcare Conference
For personal use only 39 Annual JP Morgan Healthcare Conference | January 11 - 14, 2021 th
Slide 2: Chief Executive Officer Paul Rennie
Paradigm Pharmaceuticals | JP Morgan Presentation 02 For personal use only Chief Executive Officer Paul Rennie arrow-right
Slide 3: Disclaimer
Paradigm Pharmaceuticals | JP Morgan Presentation 03 Disclaimer For personal use only This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this
Slide 4: Changing the paradigm around where the greatest potential lies
Paradigm Pharmaceuticals | JP Morgan Presentation 04 Changing the paradigm For personal use only around where the greatest potential lies. Paradigm Biopharma ASX:PAR is approaching unmet needs from a completely different angle. As repurposing experts, we are developing new solutions by identifying u
Slide 5: Experts in uncovering the real value of a molecule
Paradigm Pharmaceuticals | JP Morgan Presentation 05 Paradigm For personal use only Experts in uncovering the real value of a molecule Biopharma is a commercially focused drug (Re)Pioneers of PPS (Re)Pioneers of... repurposing Shifting the paradigm in Tx of... Shifting the paradigm in Tx of... compa
Slide 6: Blockbuster market opportunity
Paradigm Pharmaceuticals | JP Morgan Presentation 06 72 Blockbuster For personal use only Total prevalence of OA in key markets Knee and Hip market opportunity M+ and growing 69 % Zilosul meets a ® OA patients dissatisfied with current significant treatments1 unmet need in osteoarthritis USA CAN EU5
Slide 7: Recent OA Transactions
Paradigm Pharmaceuticals | JP Morgan Presentation 07 Recent OA For personal use only COMPANIES COMPOUND REGION UPFRONT TOTAL VALUE STATUS Transactions Anti-NGF Global US$200m US$1.8bn NDA Submitted Anti-NGF Global US$250m US$1.25bn Phase 3 Highlights Pharma Corticosteroid Global Take-over* US$1.0bn*
Slide 8: Confident of clinical success
Paradigm Pharmaceuticals | JP Morgan Presentation 08 Confident For personal use only PPS of clinical success NF-KB • Multiple modes of action • Previous Phase IIb, SAS and EAP experience • Global harmonised clinical trial consultation arrow-down Inflammation arrow-down Pain Cartilage Protection Impr
Slide 9: Summary Phase 2B data
Paradigm Pharmaceuticals | JP Morgan Presentation 09 Summary Phase 2B data Phase 2B double blinded, placebo controlled trial. N=112 For personal use only PAIN PAIN – – Mean Mean Change Change KOOS KOOS Pain Pain from from BL BL (PPP (PPP NRS NRS 4-6) 4-6) FUNCTION FUNCTION – – Activities Activities
Slide 10: Exclusive Supply & Manufacturing
Paradigm Pharmaceuticals | JP Morgan Presentation 10 Exclusive For personal use only Supply & Manufacturing bene PPS pharma Chem • Long term exclusive supply agreement Buy per/kg with bene pharmaChem GmbH • Bene pharmaChem: original developer of PPS and only FDA-approved manufacturer. • Johnson & Jo
Slide 11: Strong Patents & IP Position
Paradigm Pharmaceuticals | JP Morgan Presentation 11 Strong For personal use only Minimum life on patents Patents & IP Patent protection using is 2030 and beyond for PPS for new indications more recent patents i.e. 2035 - 2040 Position Established regulatory Patents for MPS (ex Multi-faceted exclusi
Slide 12: Global Harmonisation
Paradigm Pharmaceuticals | JP Morgan Presentation 12 Feedback from EMA + FDA: For personal use only Global Harmonisation FDA: Pre-IND meeting EMA Scientific Advice FDA: Type C meeting Harmonized OA Program Submit IND FEB SEP DEC Q1 20 20 20 21 Conducted additional pre-clinical evaluations Revised Cl
Slide 13: Overall Clinical Program for OA
Paradigm Pharmaceuticals | JP Morgan Presentation 13 Overall Clinical Program for OA OA_009 IA Safety For personal use only OA_010 LSLV OA_003 LSFV OA_009 FSFV OA_007 IA Safety OA_006 FSFV OA_008 LSLV OA_002 LSLV OA_006 IA Safety OA_010 FSFV OA_008 FSFV OA_002 FSFV OA_002 Dose selection OA_007 FSFV
Slide 14: Milestones and Newsflow
Paradigm Pharmaceuticals | JP Morgan Presentation 14 Milestones and Newsflow For personal use only Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 2022 2023 2024 IND Submission OA_008 Primary OA_008 Final OA_009 Interim OA_007 Interim NDA/EMA Endpoint Data Data Readout Safety Readout Safety Readout R
Slide 15: Summary
Paradigm Pharmaceuticals | JP Morgan Presentation 15 Summary For personal use only • Repurposing experts - developing new solutions and addressing unmet needs • PPS - first asset - with multi-faceted IP and patent protection • Exclusive, scalable supply agreements • Unique multi-modal action - rich
Slide 16: For personal use only
Paradigm Pharmaceuticals | JP Morgan Presentation 16 For personal use only arrow-right For more information please visit: paradigmbiopharma.com or email any queries to investorrelations@paradigmbiopharma.com times
Paradigm Biopharmaceuticals — 39th Annual JP Morgan Healthcare Conference 2021 on 6ix